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Background: Follicular bronchiolitis is a histopathologic finding that occurs in diverse
clinical contexts. The current study was conducted to characterize clinico-radiologic
features, and assess outcomes associated with follicular bronchiolitis.
Subjects and methods: Twelve subjects with follicular bronchiolitis on lung biopsy were
seen over a 9-year period, between 1996 and 2005. Medical records, biopsy and
radiographic findings, and details of outcome at the time of last follow-up were recorded.
Results: The study population included 4 men and 8 women; the median age at diagnosis
was 54 years (range, 33–81 years). Four patients had underlying systemic diseases that
included: 2 with common variable immunodeficiency, 1 Sjo¨gren’s syndrome and 1
undifferentiated connective tissue disease. The diagnosis was obtained by surgical lung
biopsy in all cases. Follicular bronchiolitis was the major histologic pattern in 9 patients;
organizing pneumonia, nonspecific interstitial pneumonia and usual interstitial pneumonia
was seen in 1 patient each with follicular bronchiolitis being an associated secondary
histopathologic component. Computed tomographic findings included reticular opacities,
small nodules and ground-glass opacities. Clinical course was characterized by relative
stability with partial response to immunosuppressive agents. During a median follow-up
period of 47 months, only one death occurred—out of 9 patients where the outcome
information was available—and was unrelated to lung disease.
Conclusions: The histologic lesion of follicular bronchiolitis may be seen as the
predominant finding or a relatively minor feature in interstitial pneumonias. The clinicalElsevier Ltd. All rights reserved.
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progressive lung disease is uncommon.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Follicular bronchiolitis is an uncommon bronchiolar disorder
characterized by the presence of hyperplastic lymphoid
follicles with reactive germinal centers distributed along
bronchovascular bundles.1–3 Follicular bronchiolitis can also
occur as a secondary finding in a variety of lung diseases.
When it occurs in isolation, follicular bronchiolitis is a form
of primary airway-centered lymphoid hyperplasia that is
often associated with systemic diseases such as connective
tissue disease or immunodeficiency syndromes.1–4 Relatively
little is known regarding prognostic implications and
treatment of follicular bronchiolitis. Additionally, the
relationship of follicular bronchiolitis to idiopathic inter-
stitial pneumonias remains to be clarified.
In an effort to further characterize the clinical features
and outcomes associated with follicular bronchiolitis, we
identified 12 patients with follicular bronchiolitis on surgical
lung biopsies and examined the clinical and radiologic
presentation of these subjects, as well as their clinical
course and outcome.
Subjects and methods
We conducted a computer-assisted search of the Mayo Clinic
database to identify cases of follicular bronchiolitis seen in
adults (21 years of age or older) at our institution over a 9-
year period, June 1, 1996 through May 31, 2005. Twelve
patients were identified; relevant medical records and
imaging studies were reviewed. Surgical lung biopsy speci-
mens were reviewed by one of us (J.L.M.) to confirm the
histopathologic diagnosis of follicular bronchiolitis. Histolo-
gic diagnosis of follicular bronchiolitis required the presence
of hyperplastic lymphoid follicles limited to distal cartila-
ginous airways and bronchioles without histologic or
immunophenotypic evidence of malignant lymphoma.
Eventual clinical outcome was assessed at the time of the
last available follow-up and categorized as improved, stable
or worsened using the changes in respiratory symptoms,
radiologic findings and pulmonary function measurements
(total lung capacity, vital capacity, diffusing capacity to
carbon monoxide and oxygen saturation or PaO2) as
described in a consensus statement from the American
Thoracic Society/European Respiratory Society.5 This study
was approved by the Mayo Foundation institutional review
board. Patients who did not authorize the use of their
medical records for research were excluded from this study.
Results
Underlying systemic disease was present in 4 patients and
included common variable immunodeficiency syndrome in 2
patients, and 1 patient each with Sjo¨gren’s syndrome and
undifferentiated connective tissue disease (Table 1). Nocause or associated systemic disease could be identified, or
developed, in the remaining 8 patients, i.e. these were
idiopathic cases. Four of these 8 patients had an elevated
antinuclear antibody titer or rheumatoid factor in the serum
but there were no clinical features of connective tissue
disease (Table 1). Three patients (25%) were current
smokers at the time of diagnosis, 2 patients were prior
smokers (17%), while the majority (7 out of 12 or 58%) were
lifelong non-smokers.
Ten patients had pulmonary function results available,
including 6 obtained prior to initiating treatment. Four
patients (40%) had a restrictive pattern of ventilatory
limitation and 3 other patients (30%) had a nonspecific
pattern of abnormalities (reduced diffusing capacity). Three
remaining patients (30%) had normal pulmonary function
results; an obstructive pattern was not observed. Overall,
the most common pulmonary function abnormality was a
reduced diffusing capacity which was observed in 7 of 10
patients. Pulmonary function test results were available in 6
of the 8 patients with idiopathic follicular bronchiolitis and
are summarized in Table 2.
Chest radiography was available in 10 patients and
demonstrated relatively nonspecific findings consisting of
bilateral interstitial changes in most patients (Table 3). Two
patients (20%) had normal chest radiographs. Eleven of the
12 patients had CT scans performed and all were abnormal.
CT findings were variable and included reticular opacities,
nodules, ground-glass opacities and patchy consolidation.
Five patients (45%) had mediastinal or hilar lymphadeno-
pathy (Table 3). Two patients had traction bronchiectasis
seen on CT; patients with nonspecific interstitial pneumonia
and usual interstitial pneumonia, respectively. In 2 patients
with normal chest radiograph, CT scan revealed micronod-
ular infiltrates and patchy ground-glass opacities, respec-
tively. Among 9 patients in whom follicular bronchiolitis was
the predominant histopathologic finding, 8 had CT scans
available and demonstrated ground-glass opacities and/or
small nodules (Figure 1A and B) in all except one patient.
Most patients were treated with prednisone, sometimes
in combination with azathioprine, with a generally favorable
response (Table 1). Eight of the 12 patients (67%) underwent
a trial of prednisone treatment with a median daily dose
of 40mg (range, 20–60mg). Symptomatic improvement
(improved cough, dyspnea or both) with prednisone treat-
ment was noted in 6 of these patients (75%). Objective
improvement with prednisone treatment, as evidenced by
improvement in pulmonary function measurements or
parenchymal infiltrates seen on chest radiography or CT,
was noted in all 8 patients. A trial of macrolide therapy
(azithromycin 250mg orally once every Monday, Wednesday
and Friday) was administered in one of these patients who
had had become corticosteroid-dependent. On macrolide
treatment, the corticosteroid dose was gradually discon-
tinued, and the patient experienced continued subjective
and objective improvement. One patient was asymptomatic
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Table 1 Demographic, clinical and histologic features for 12 patients with follicular bronchiolitis.
Age, sex Underlying
disease
Major histologic
finding
Minor histologic
finding
Treatment Outcome
51, female – FB – Prednisone Not available
61, male – FB – Prednisone,
azathioprine,
mycophenolate
Improved at 54
months
58, female Sjo¨gren’s
syndrome
FB Non-necrotizing
granulomas
Prednisone Inactive disease
at 103 months
81, male – OP FB None Died of
metastatic
melanoma at 46
months
36, male CVID FB DIP Prednisone Improved
infiltrates at 10
months
33, female – FB Carcinoid
tumorlets
Prednisone,
azathioprine
Stable at 52
months
48, male – FB Emphysema None Stable at 50
months
60, female Undifferentiated
CTD
UIP FB Prednisone,
azathioprine
Improved at 48
months
46, female – NSIP FB Prednisone Not available
45, female – FB – Prednisone,
azithromycin
Improved at 17
months
79, female – FB – Prednisone,
azathioprine
Slow decline at
107 months
53, female CVID FB – None Not available
FB, follicular bronchiolitis; DIP, desquamative interstitial pneumonia; CVID, common variable immunodeficiency; CTD, connective
tissue disease; NSIP, nonspecific interstitial pneumonia.
The mean duration of follow-up after histopathologic diagnosis was 47 months.
Follicular bronchiolitis in surgical lung biopsies 309at presentation with normal pulmonary function results, and
continues to remain stable on no therapy at 50 months
follow-up after initial abnormal CT scan.
There were no deaths related to follicular bronchiolitis
or progressive respiratory disease. One patient died from
metastatic melanoma at 4 years after the diagnosis of
follicular bronchiolitis. Development of secondary pulmon-
ary lymphoma did not occur in any of the patients in this
series.Discussion
Follicular bronchiolitis is an uncommon pulmonary disorder
characterized by expansion of lymphoid tissue in the
peribronchiolar regions associated with mild degrees of
lymphocytic and monocytoid cell infiltration in the inter-
stitium.1,2,4,6,7 The histologic lesion of follicular bronchio-
litis may be seen as the predominant finding or a relatively
minor feature in interstitial pneumonias. Objective im-
provement in lung function is commonly observed with
corticosteroid therapy. The current report suggests that
macrolide therapy may be an alternative to corticosteroids
in some patients with follicular bronchiolitis. The clinical
course and prognosis for most patients with follicularbronchiolitis is relatively good, and progressive lung disease
is uncommon.
Most of the patients in the current series presented with
respiratory symptoms and abnormal chest radiographs of
nonspecific character. Pulmonary function testing demon-
strated either a nonspecific or restrictive pattern of
abnormalities; none had an obstructive defect. CT scan
findings were variable but follicular bronchiolitis was
associated mainly with findings of small nodules and/or
ground-glass opacities as previously reported by Howling et
al.3 However, we note that the radiologic findings in our
study were more heterogeneous than those described by
Howling. This is likely explained by inclusion of only those
patients in whom the follicular bronchiolitis was the sole or
predominant histologic abnormality in Howling’s study,
whereas we included patients in whom follicular bronchio-
litis was not the predominant histologic finding. The
distribution of nodular infiltrates may suggest the possibility
of bronchiolar disease in some of these patients, but the CT
appearance is by no means specific for follicular bronchio-
litis.1,3
In previous studies, the majority of patients with
follicular bronchiolitis had identifiable underlying diseases
including connective tissue diseases, other autoimmune
disorders, inflammatory bowel disease and immunodeficiency
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Table 2 Pulmonary function.
Characteristic Idiopathic FB
(N ¼ 6)
Entire group
(N ¼ 10)y
Total lung capacity—% predicted
Mean 83.6 82
Range 60–105
Residual volume—% predicted
Mean 118.6 107
Range 49–163
FVC—% predicted
Mean 72 77.9
Range 47–117
FEV1—% predicted
Mean 71.2 78
Range 50–112
Carbon monoxide diffusing capacity—% predicted
Mean 61.8 66.9
Range 44–85
For the subgroup of patients with primary follicular
bronchiolitis, total lung capacity and residual volume
measurements were available in 5 out of 6 patients.
yTotal lung capacity values were available for 7, residual
volume for 6, FVC and FEV1 values for 9 and carbon monoxide
diffusing capacity for 10 patients.
Table 3 Radiologic features.
Characteristic No. (%)
Chest radiographic findings
Bilateral interstitial 7 (70)
Mixed alveolar and interstitial infiltrates 1 (10)
Normal 2 (20)
CT findingsy
Reticular opacities 6 (55)
Centrilobular nodules 5 (45)
Ground-glass opacities 5 (45)
Mediastinal or hilar lymphadenopathy 5 (45)
Traction bronchiectasis 2 (18)
Airspace consolidation 2 (18)
Emphysema 1 (9)
Chest radiograph was available in 10 patients.
yCT chest was available in 11 patients.
M.R. Aerni et al.310syndromes.3,6 For example, Howling’s study,3 consisted of 12
patients with follicular bronchiolitis all of whom had
systemic diseases that included connective tissue disease
in 10 (rheumatoid arthritis in 8), ‘‘autoimmune disorder’’ in
1, and acquired immunodeficiency syndrome (AIDS) in the
remaining patient. However, Romero et al.,4 recently
described 6 patients with follicular bronchiolitis diagnosed
by surgical lung biopsy with only 1 patient having an
underlying disease, AIDS. Of the remaining 5 patients,
4 were idiopathic and 1 had prolonged exposure topolyethylene flock. Similarly, we were unable to identify
an underlying disease in two-thirds of our 12 patients with
follicular bronchiolitis. Thus, absence of an identifiable
systemic disease should not dissuade consideration of
follicular bronchiolitis in the differential diagnosis for a
patient with suggestive clinico-radiologic features.
As in any other cause of bronchoilitis, bronchoscopy
appears to have a minor role in the diagnosis of follicular
bronchiolitis. The vast majority of patients with follicular
bronchiolitis described in previous reports have had their
diagnosis confirmed by surgical lung biopsy.2,4,8 All of our 12
patients underwent surgical lung biopsy for diagnosis;
bronchoscopic biopsy in 6 patients had been nondiagnostic.
As in virtually every cause of primary bronchiolar disease,
bronchoscopic biopsy is unlikely to be diagnostic due to
sampling error [patchy nature of the disease], and insuffi-
cient amount of representative tissue obtained.
Most of the patients described in previous reports as well
as in our study were treated with corticosteroids, sometimes
in combination with another immunosuppressive drug such
as azathioprine or methotrexate.2,4 In general, patients with
follicular bronchiolitis appear to respond favorably to
corticosteroid therapy. Initial improvement may be followed
by relapse of the disease as the corticosteroid dose is
tapered. The role of other immunosuppressive drugs in the
treatment of follicular bronchiolitis remains unclear. One of
our patients was treated with macrolide therapy (azithro-
mycin) with favorable results. Macrolides have been used for
their immuno-modulatory and anti-inflammatory properties
in several respiratory diseases including asthma, cystic
fibrosis and diffuse panbronchiolitis.9–13 Diffuse panbronch-
iolitis is a disease that has been described mainly in
Japanese adults and rarely in the Western hemisphere.13,14
It is a distinct clinicopathologic syndrome that is character-
ized by bronchiolar inflammation and chronic sinusitis.
Although the pathogenesis of diffuse panbronchiolitis
is not known, prolonged treatment with erythromycin
improves respiratory symptoms, lung function and survi-
val.13–16 Hayakawa et al.17 described significant improve-
ment of symptoms with erythromycin therapy in several
rheumatoid patients with inflammatory bronchiolar lesions
consistent with follicular bronchoilitis, although in their
series, macrolides were found to be more effective in the
management of the control group with diffuse panbronch-
iolitis. A variety of macrolides have been demonstrated to
alter immune responses in both in vitro and in vivomodels of
inflammation.9,13 These studies suggest a role for macrolides
as potentially useful pharmacologic agents in the treatment
of inflammatory lung diseases such as follicular bronchioli-
tis. The role of macrolide therapy in the treatment of
follicular bronchiolitis deserves to be explored further.
Histologic features of follicular bronchiolitis can overlap
with other lymphoproliferative lesions, most notably lym-
phoid interstitial pneumonia. Distinction between lymphoid
interstitial pneumonia and follicular bronchiolitis is based
mainly on the extent of lymphocytic infiltration. In follicular
bronchiolitis, the lymphoid follicles and mononuclear cell
infiltration are predominantly peribronchial and peribronch-
iolar. However, in lymphoid interstitial pneumonia, the
interstitial infiltration is more diffuse and expands alveolar
septa. Follicular bronchoilitis and lymphoid interstitial
pneumonia sometimes have to be carefully distinguished
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Figure 1 High-resolution CT of a 53-year-old woman with follicular bronchiolitis confirmed on surgical lung biopsy. (A) This image
demonstrates numerous micronodules (arrows) suggestive of bronchiolar disease in both lower lobes. (B) Patchy ground-glass
opacities (arrows) are seen in the apices, particularly on the right side.
Follicular bronchiolitis in surgical lung biopsies 311from a low-grade lymphoma. This distinction usually
requires immunohistochemical analysis and molecular gene
rearrangement studies to determine clonal rearrangement
of the immunoglobulin heavy chain gene.
Similar to previous reports,2,4 follicular bronchiolitis was
associated with a generally good prognosis and appeared to
respond favorably to corticosteroid therapy. No deaths
occurred from respiratory causes among our 12 patients.
We conclude that follicular bronchiolitis can occur without
underlying connective tissue disease or immunodeficiency
syndrome and is associated with a relatively favorable
clinical course. Corticosteroid therapy has been used most
commonly and appears to provide clinical benefit for
patients with follicular bronchiolitis. The role of macrolides
in the treatment of follicular bronchiolitis should be
explored further.Conflict of interest
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